Abstract |
Pancreatic ductal adenocarcinoma(PDAC) does not respond to single-agent immune checkpoint inhibitor therapy, including anti-PD-1 antibody(aPD-1) therapy. Higher plasma levels of IL-8 are associated with poorer outcomes in patients who receive aPD-1 therapies, providing a rationale for combination immunotherapy with an anti-IL-8 antibody(aIL-8) and aPD-1. We thus investigated whether human aIL-8 therapy can potentiate the antitumor activity of aPD-1 and further investigated how the combination affects the immune response by regulating myeloid cells in the tumor microenvironment in a humanized murine model of PDAC with a reconstituted immune system consisting of human T cells and a combination of CD14+ and CD16+ myeloid cells. The results show that the combination of aIL-8 and aPD-1 treatment significantly enhanced antitumor activity following the infusion of myeloid cells. Our results further showed that the target of IL-8 is mainly present in CD16+ myeloid cells and is likely to be granulocytes. FACS analysis showed that aIL-8 treatment increased granulocytic myeloid cells in tumors. Consistently, single- nuclear RNA-sequencing analysis of tumor tissue showed that the innate immune response and cytokine response pathways in the myeloid cell cluster were activated by aIL-8 treatment. This is the first preclinical study using a humanized mouse model for new combination immunotherapeutic development and supports the further clinical testing of aIL-8 in combination with aPD-1 for PDAC treatment. This study also suggests that peripherally derived myeloid cells can potentiate the antitumor response of T cells, likely through the innate immune response, and aIL-8 re-educates tumor-infiltrating myeloid cells by activating the innate immune response.
|
Authors | Pan Li, Noah Rozich, Jianxin Wang, Junke Wang, Yao Xu, Brian Herbst, Raymond Yu, Stephen Muth, Nan Niu, Keyu Li, Vanessa Funes, Jessica Gai, Arsen Osipov, Barish H Edil, Christopher L Wolfgang, Ming Lei, Tingbo Liang, Lei Zheng |
Journal | Cancer letters
(Cancer Lett)
Vol. 539
Pg. 215722
(07 28 2022)
ISSN: 1872-7980 [Electronic] Ireland |
PMID | 35533951
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022. Published by Elsevier B.V. |
Chemical References |
|
Topics |
- Animals
- Carcinoma, Pancreatic Ductal
(drug therapy, metabolism)
- Disease Models, Animal
- Humans
- Interleukin-8
- Mice
- Myeloid Cells
(metabolism)
- Pancreatic Neoplasms
(drug therapy, metabolism)
- Tumor Microenvironment
|